Merck Biopharma Innovation Cup 2017

MerckMerck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent. It showcases Merck's deep commitment to leverage innovation, curiosity and collaboration. With more than 1,400 applications from 60 countries, this year's Biopharma Innovation Cup achieved a new record of popularity. Thirty-three participants worked hand in hand with experienced Merck researchers and managers in the biopharma field on developing business plans. For 6 days, bright minds came together at the Innovation Camp near Frankfurt, Germany, and jointly developed novel ideas into innovative project plans for drug discovery.

The winning team "Immuno-Oncology" inspired the audience with their outstanding project proposal on how to translate NK cell biology into a drug discovery project.

The team consisted of:

  • Alex Kertser (Weizmann Institute of Science, Israel)
  • Franklin Zhong (A*STAR, Singapore)
  • Kelly Moynihan (MIT, USA)
  • Patrik Andersson (Karolinska Institute, Sweden)
  • Simone Mori (The Scripps Research Institute, USA)
  • Arne Sutter (team coach)

As runner-up receiving €5,000, the team "Medicinal Chemistry" was chosen with an innovative proposal on DNA-encoded libraries.

The team consisted of:

  • Adam McCallum (Georgia Institute of Technology, USA)
  • Anna Rydzik (LMU Munich, Germany)
  • Josua Jordi (Harvard, USA)
  • Rüdiger Borrmann (ETH Zürich, Switzerland)
  • Wilian Cortopassi (UCSF, USA)
  • Henning Böttcher (team coach)

The initiative has won several innovation awards over the years, including the Edison Award 2017, Stevie Gold Award 2017, German Industry Innovation Award 2015 and the German Idea Award 2014. More detailed information on the Biopharma Innovation Cup can be found at Biopharma Open Innovation Portal.

"The Biopharma Innovation Cup is getting increasingly popular at innovation hotspots all over the world from year to year. We are happy to offer young talents this development opportunity," said Dr Ulrich Betz, Vice President of Innovation & Entrepreneurship Incubator at the Healthcare business of Merck and initiator and manager of the Innovation Cup.

On the occasion of their 350th anniversary in 2018, Merck will conduct a special anniversary edition of the Innovation Cup, covering topics in Life Science and Performance Materials in addition to Healthcare. Applications to participate in the 2018 edition of the cup can be submitted starting October 01, 2017, here: http://innovationcup.merckgroup.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]